First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE ® Immunotherapy Platform Across Hematologic Malignancies BLINCYTO ® ...
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the ...
MELBOURNE, Australia--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12 th World Congress ...
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased ...
Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the ...
These observed declines were consistent with the inhibition of androgen receptor signaling. MDV3100 continued to be well-tolerated in all dose groups. The data were presented as part of a special late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback